CO129 Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy (RWPC) for Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.201
https://www.valueinhealthjournal.com/article/S1098-3015(23)03331-4/fulltext
Title :
CO129 Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy (RWPC) for Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03331-4&doi=10.1016/j.jval.2023.09.201
First page :
Section Title :
Open access? :
No
Section Order :
11388